Scarica l'app Stockscreener
4.84
3.42%
0.16
Dopo l'orario di chiusura:
4.93
0.09
+1.86%
Precedente Chiudi:
$4.68
Aprire:
$4.69
Volume 24 ore:
79,802
Relative Volume:
0.31
Capitalizzazione di mercato:
$101.27M
Reddito:
-
Utile/perdita netta:
$-14.88M
Rapporto P/E:
-4.9388
EPS:
-0.98
Flusso di cassa netto:
$-10.29M
1 W Prestazione:
+8.04%
1M Prestazione:
-11.52%
6M Prestazione:
-27.44%
1 anno Prestazione:
-17.83%
Intervallo 1D:
$4.662
$4.86
Intervallo di 1 settimana:
$4.37
$4.86
Portata 52W:
$3.9401
$8.29
Coya Therapeutics Inc Stock (COYA) Company Profile
Nome
Coya Therapeutics Inc
Settore
Industria
Telefono
650.739.3939
Indirizzo
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Confronta COYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.84 | 97.93M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Lake Street | Buy |
| 2024-12-04 | Iniziato | D. Boral Capital | Buy |
Coya Therapeutics Inc Borsa (COYA) Ultime notizie
(COYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Coya Therapeutics (COYA): Analyst Maintains 'Buy' Rating with St - GuruFocus
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics advances ALS and FTD clinical trials in 2026 By Investing.com - Investing.com India
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - PharmiWeb.com
Coya Therapeutics Reports Strong Cash Position and Runway - TipRanks
Coya Therapeutics advances ALS and FTD clinical trials in 2026 - Investing.com
Will Coya Therapeutics Inc outperform its industry peers2025 Winners & Losers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Momentum Shift: Is PHAT currently under institutional pressureQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
COYA-302: De-Risked Treg Platform With Compelling FTD Data and ALS Phase 2 Catalyst Supporting Buy Rating - TipRanks
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Can Candel Therapeutics Inc. stock attract ESG capital inflows2025 Momentum Check & Consistent Return Strategy Ideas - ulpravda.ru
Is Coya Therapeutics Inc. stock a safe buy before earnings2025 AllTime Highs & Verified High Yield Trade Plans - Улправда
Is Coya Therapeutics Inc. stock a bargain at current levels2025 Year in Review & High Accuracy Swing Entry Alerts - Улправда
Is Coya Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Is Coya Therapeutics Inc. stock cheap compared to fundamentals2025 Key Lessons & Technical Pattern Based Buy Signals - Улправда
Support Test: How CERo Therapeutics Holdings Inc. stock benefits from global expansionTrade Analysis Report & Weekly Stock Performance Updates - ulpravda.ru
Chardan Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Aug Intraday: How Coya Therapeutics Inc. stock reacts to job market dataJuly 2025 Price Swings & Comprehensive Market Scan Reports - Улправда
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating - TipRanks
Coya Therapeutics, Inc. Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - marketscreener.com
How Coya Therapeutics Inc. stock reacts to job market data2025 Price Momentum & Entry and Exit Point Strategies - ulpravda.ru
COYA: Analyst Maintains Buy Rating and $15 Target Price | COYA S - GuruFocus
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data - TipRanks
Coya Therapeutics Announces Positive Study Results for FTD Treatment - TradingView — Track All Markets
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Panic Selling: How Coya Therapeutics Inc stock reacts to job market dataMarket Volume Report & Technical Pattern Recognition Alerts - moha.gov.vn
Coya Therapeutics, Inc.Common Stock (NQ: COYA - FinancialContent
Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target - TipRanks
Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital - Defense World
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for CO - PharmiWeb.com
Coya Therapeutics announces FDA acceptance of COYA 302 IND application - TipRanks
US COYA 302 trial in ALS expands to Canada after regulatory nod - ALS News Today
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18 - Investing.com Canada
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - BioSpace
COYA Stock Receives Consistent "Buy" Rating from D. Boral Capita - GuruFocus
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
(COYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Coya announces Health Canada acceptance of COYA 302 clinical trial application - MSN
S P Trends: Will Coya Therapeutics Inc stock pay special dividendsJuly 2025 Price Swings & Long-Term Safe Return Strategies - Bộ Nội Vụ
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Is Coya Therapeutics Stock Built to Withstand More Downside? - Trefis
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics receives clinical trial application acceptance from Health Canada - marketscreener.com
Coya Therapeutics, Inc. Receives Clinical Trial Application Acceptance from Health Canada to Proceed with the COYA302 Alstars Trial for the Treatment of Amyotrophic Lateral Sclerosis - marketscreener.com
PRN_FinancialWrapper - FinancialContent
Coya Therapeutics Inc Azioni (COYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):